

# Douglas B Cines

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/472085/publications.pdf>

Version: 2024-02-01

86  
papers

10,948  
citations

81743

39  
h-index

62479

80  
g-index

87  
all docs

87  
docs citations

87  
times ranked

8377  
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. <i>Blood</i> , 2022, 139, 1564-1574.	0.6	55
2	Mesenchymal stromal cells enhance self-assembly of a HUVEC tubular network through uPA-uPAR/VEGFR2/integrin/NOTCH crosstalk. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022, 1869, 119157.	1.9	8
3	Thrombocytopenia following Pfizer and Moderna <sc>SARSâ€CoV</sc>â€2 vaccination. <i>American Journal of Hematology</i> , 2021, 96, 534-537.	2.0	331
4	Functional NMDA receptors are expressed by human pulmonary artery smooth muscle cells. <i>Scientific Reports</i> , 2021, 11, 8205.	1.6	12
5	Alphaâ€defensins: risk factor for thrombosis in COVIDâ€19 infection. <i>British Journal of Haematology</i> , 2021, 194, 44-52.	1.2	15
6	SARS-CoV-2 Vaccineâ€Induced Immune Thrombotic Thrombocytopenia. <i>New England Journal of Medicine</i> , 2021, 384, 2254-2256.	13.9	412
7	Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes. <i>Blood</i> , 2021, 138, 2106-2116.	0.6	23
8	COVID-19 vaccination and immune thrombocytopenia. <i>Nature Medicine</i> , 2021, 27, 1145-1146.	15.2	29
9	Erythrocytes identify complement activation in patients with COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L485-L489.	1.3	39
10	Thrombocytopenia in pregnancy: Diagnosis and approach to management. <i>Blood Reviews</i> , 2020, 40, 100638.	2.8	31
11	COVID-19â€associated Acute Respiratory Distress Syndrome Clarified: A Vascular Endotype?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 750-753.	2.5	36
12	Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation. <i>Blood</i> , 2020, 135, 1270-1280.	0.6	55
13	Diagnosing HIT: the need for speed. <i>Blood</i> , 2020, 135, 1082-1083.	0.6	5
14	Pathogenesis of heparin-induced thrombocytopenia. <i>Translational Research</i> , 2020, 225, 131-140.	2.2	61
15	FcRn augments induction of tissue factor activity by IgG-containing immune complexes. <i>Blood</i> , 2020, 135, 2085-2093.	0.6	19
16	The risk of major bleeding in patients with suspected heparinâ€induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1956-1965.	1.9	42
17	Human neutrophil peptideâ€1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 596-606.	1.9	9
18	American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3829-3866.	2.5	684

#	ARTICLE	IF	CITATIONS
19	T2 Magnetic Resonance to Monitor Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 247-252.	1.5	3
20	Blood clot contraction differentially modulates internal and external fibrinolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 361-370.	1.9	57
21	Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK. <i>Translational Stroke Research</i> , 2019, 10, 104-111.	2.3	53
22	Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-“oncologists. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 24-30.	1.0	11
23	tPA variant tPA <sup>296-299</sup> Prevents impairment of cerebral autoregulation and necrosis of hippocampal neurons after stroke by inhibiting upregulation of ET-1. <i>Journal of Neuroscience Research</i> , 2018, 96, 128-137.	1.3	8
24	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2018, 2, 3360-3392.	2.5	448
25	Neutrophil accumulation and NET release contribute to thrombosis in HIT. <i>JCI Insight</i> , 2018, 3, .	2.3	115
26	Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway. <i>Blood</i> , 2018, 132, 2431-2440.	0.6	35
27	Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2018, 2, 3155-3162.	2.5	38
28	Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT). <i>Autoimmunity Reviews</i> , 2018, 17, 1046-1052.	2.5	11
29	Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia. <i>Blood</i> , 2018, 132, 727-734.	0.6	9
30	Thrombocytopenia in pregnancy. <i>Blood</i> , 2017, 130, 2271-2277.	0.6	100
31	Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-“reperfusion injury. <i>FASEB Journal</i> , 2017, 31, 761-770.	0.2	27
32	Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond. <i>Transfusion Medicine Reviews</i> , 2017, 31, 26-35.	0.9	67
33	Thrombocytopenia in pregnancy. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 144-151.	0.9	40
34	ICAM-1-“targeted thrombomodulin mitigates tissue factor-“driven inflammatory thrombosis in a human endothelialized microfluidic model. <i>Blood Advances</i> , 2017, 1, 1452-1465.	2.5	26
35	Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. <i>Journal of Clinical Investigation</i> , 2017, 127, 1090-1098.	3.9	37
36	Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2016, 1, 62-74.	2.5	58

#	ARTICLE	IF	CITATIONS
37	Role of monocytes and endothelial cells in heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 806-812.	1.8	15
38	ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model. <i>Transfusion</i> , 2016, 56, 1775-1785.	0.8	16
39	ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro. <i>Transfusion</i> , 2016, 56, 1763-1774.	0.8	29
40	Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia. <i>Blood</i> , 2016, 127, 464-472.	0.6	86
41	Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood. <i>Blood</i> , 2016, 127, 149-159.	0.6	133
42	Tissue-Type Plasminogen Activator-A <sup>296</sup> Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38. <i>Stroke</i> , 2016, 47, 2096-2102.	1.0	9
43	Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. <i>Blood</i> , 2016, 128, 110-119.	0.6	59
44	Î±-Defensins Induce a Post-translational Modification of Low Density Lipoprotein (LDL) That Promotes Atherosclerosis at Normal Levels of Plasma Cholesterol. <i>Journal of Biological Chemistry</i> , 2016, 291, 2777-2786.	1.6	16
45	Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT). <i>Autoimmunity Reviews</i> , 2016, 15, 752-755.	2.5	17
46	Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. <i>Blood</i> , 2015, 125, 2558-2567.	0.6	109
47	Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. <i>Blood</i> , 2015, 125, 3326-3334.	0.6	30
48	Can Immune Thrombocytopenia Be Cured with Medical Therapy?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 395-404.	1.5	63
49	Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier. <i>Therapeutic Delivery</i> , 2015, 6, 795-826.	1.2	91
50	Atomic description of the immune complex involved in heparin-induced thrombocytopenia. <i>Nature Communications</i> , 2015, 6, 8277.	5.8	101
51	A Microfluidic Model of Microvascular Inflammation: Characterization and Testing of Endothelial-Targeted Therapeutics. <i>Blood</i> , 2015, 126, 3454-3454.	0.6	1
52	Membrane Remodeling By Pathogenic Antibodies Underlies Monocyte Activation in Heparin-Induced Thrombocytopenia. <i>Blood</i> , 2015, 126, 2244-2244.	0.6	1
53	Human Neutrophil Peptides (HNPs) Enhance Thrombus Formation Under Flow By Inhibiting Proteolytic Activity of Plasma ADAMTS13 Metalloprotease. <i>Blood</i> , 2015, 126, 105-105.	0.6	0
54	T2 Magnetic Resonance: A Diagnostic Platform for Studying Integrated Hemostasis in Whole Blood-Proof of Concept. <i>Clinical Chemistry</i> , 2014, 60, 1174-1182.	1.5	26

#	ARTICLE	IF	CITATIONS
55	Dynamic antibody-binding properties in the pathogenesis of HIT. <i>Blood</i> , 2012, 120, 1137-1142.	0.6	65
56	Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders. <i>Blood</i> , 2012, 120, 4134-4142.	0.6	6
57	Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. <i>Blood</i> , 2011, 118, 2882-2888.	0.6	30
58	Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. <i>Blood</i> , 2010, 116, 5021-5031.	0.6	134
59	Neutrophil $\alpha$ -Defensins Cause Lung Injury by Disrupting the Capillary Epithelial Barrier. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 935-946.	2.5	73
60	The ITP syndrome: pathogenic and clinical diversity. <i>Blood</i> , 2009, 113, 6511-6521.	0.6	662
61	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. <i>Blood</i> , 2009, 113, 2386-2393.	0.6	2,128
62	Visualizing the Molecular and Cellular Basis of Heparin Induced Thrombocytopenia.. <i>Blood</i> , 2009, 114, 228-228.	0.6	0
63	Monocytes Are a Particularly Favorable Target for Surface Platelet Factor 4 (PF4) Antigenic Complex Formation in Heparin-Induced Thrombocytopenia: New Insights into the Thrombotic Risk in HIT. <i>Blood</i> , 2008, 112, 271-271.	0.6	1
64	Heparin-induced thrombocytopenia: An autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. <i>Journal of Clinical Apheresis</i> , 2007, 22, 31-36.	0.7	74
65	Cleaved high molecular weight kininogen (HKa) enhances the association of human $\alpha$ <sub>2</sub> <sup>v</sup> <sub>3</sub> to the complex formed by urokinase and urokinase plasminogen activator receptor (uPAR). <i>FASEB Journal</i> , 2007, 21, A178.	0.2	0
66	Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. <i>Blood</i> , 2006, 107, 2346-2353.	0.6	234
67	Erythrocyte Coupled tPA Improves Outcomes of Percussion Brain Trauma in Rats.. <i>Blood</i> , 2006, 108, 897-897.	0.6	3
68	Platelet Factor 4 (PF4) Antigenic Complexes on the Macrophage Surface: Implications for the Pathogenesis of Heparin Induced Thrombocytopenia (HIT).. <i>Blood</i> , 2006, 108, 94-94.	0.6	0
69	Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. <i>Blood</i> , 2005, 105, 131-138.	0.6	272
70	Dietary Hypercholesterolemia Enhances Heparin-Induced Thrombocytopenia/Thrombosis: A Prothrombotic Risk Factor in a Transgenic Mouse Model.. <i>Blood</i> , 2005, 106, 56-56.	0.6	1
71	Coupling Tissue Type Plasminogen Activator to Carrier Erythrocyte Protects Against Plasma Inhibitors.. <i>Blood</i> , 2005, 106, 1881-1881.	0.6	0
72	Interaction of High Molecular Weight Kininogen with Endothelial Cell Receptors suPAR, gC1qR and Cytokeratin 1 by Surface Plasmon Resonance (BiaCore).. <i>Blood</i> , 2005, 106, 2666-2666.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Inhibition of Pathological Retinal Neovascularization by $\alpha$ -Defensins.. Blood, 2005, 106, 3678-3678.	0.6	1
74	Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood, 2004, 104, 3173-3180.	0.6	140
75	Regulation of neovascularization by human neutrophil peptides ( $\alpha$ -defensins): a link between inflammation and angiogenesis. , 2004, 18, 1306.		1
76	Immune Thrombocytopenic Purpura. New England Journal of Medicine, 2002, 346, 995-1008.	13.9	1,237
77	Pathogenesis of heparin-induced thrombocytopenia and thrombosis. Autoimmunity Reviews, 2002, 1, 125-132.	2.5	33
78	Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through Fc $\gamma$ RIIA. Blood, 2001, 98, 2442-2447.	0.6	193
79	Abciximab Readministration. Circulation, 2001, 104, 870-875.	1.6	143
80	Prevalence of Heparin-Associated Antibodies Without Thrombosis in Patients Undergoing Cardiopulmonary Bypass Surgery. Circulation, 1997, 95, 1242-1246.	1.6	293
81	Defensin Modulates Tissue-type Plasminogen Activator and Plasminogen Binding to Fibrin and Endothelial Cells. Journal of Biological Chemistry, 1996, 271, 17650-17655.	1.6	72
82	Comparison of PF4/Heparin ELISA Assay With the <sup>14</sup> C-Serotonin Release Assay in the Diagnosis of Heparin-induced Thrombocytopenia. American Journal of Clinical Pathology, 1995, 104, 648-654.	0.4	206
83	Menstrual cyclic thrombocytopenia. British Journal of Haematology, 1989, 71, 519-524.	1.2	48
84	Immune Endothelial-Cell Injury in Heparin-Associated Thrombocytopenia. New England Journal of Medicine, 1987, 316, 581-589.	13.9	408
85	Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature, 1984, 309, 633-635.	13.7	412
86	Heparin-Associated Thrombocytopenia. New England Journal of Medicine, 1980, 303, 788-795.	13.9	265